Table 1 Characteristics of RCTs involved in the study
From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
Study | Patients | Scra(mg/dl) | Proteinuriaa(g/d) | Systolic BP (mmHg) | Sample sizeb | MMF | Control | Follow–up (m) | Drop-in/MMF discontinuation | Other treatment regimen | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Dose (g/d) | Duration (m) | ||||||||||
Chen et al. 2002 [20] | Grades:IV-V with interstitial inflammation area > 25%; Proteinuria > 2 g/d | NA | MMF:3.2 ± 1.7; Control:2.9 ± 1.5 | NA | 62 (31/31) | 1.0–1.5 | 12 | Steroid | 18 | NA/0 | CCB, antiplatelet when needed |
Meas et al. 2004 [21] | Grades:II-IV; Proteinuria > 1 g/d; Icr > 20 but < 70 mL/min/1.73 m2 | MMF:1.46 ± 0.08 Control: 1.39 ± 0.1 | MMF:1.9 ± 0.3; Control:1.3 ± 0.4 | MMF:122 ± 4 Control:134 ± 8 | 34 (21/13) | 2 | 36 | Placebo | 36 | NA/1 | Salt restriction, ACEI/ARB or CCB |
Frisch et al. 2005 [22] | Proteinuria > 1 g/d; Ccr > 20 but < 80 ml/min; glomerulosclerosis/tubulointerstitial fibrosis and/or crescent ≥25% | MMF:2.6 ± 1.2 Control:2.2 ± 0.72 | MMF:2.7 ± 1.6; Control:2.7 ± 1.4 | MMF:136 ± 19.2 Control:131 ± 10.6 | 32 (17/15) | Up to 2 g/d | 12 | Placebo | 24 | NA/0 | ACEI/ARB |
Tang et al. 2005 [23] | Grades:II-IV; Proteinuria > 1 g/d; | MMF:1.53 ± 0.17; Control:1.65 ± 0.23 | MMF:1.8 ± 0.21; Control:1.87 ± 0.28 | MMF:120 ± 3.2 Control:122 ± 3.2 | 40 (20/20) | 1.5–2 | 6 | Placebo | 18 | NA/0 | Salt restriction; ACEI/ARB |
Zhao et al. 2005 [24] | Grades ≥ III | All:1.6 ± 0.53 | All:2.03 ± 0.67 | NA | 31 (21/10) | 1.0–1.5 | 24 | CTX | 24 | 2/0 | Prednisone 0.6 mg/kg.d in both groups; CCB or ACEI/ARB |
Bao et al. 2007 [25] | Crescentic nephropathy; crescent ≥15% | MMF:1.21 ± 0.96; Control:1.15 ± 0.57 | MMF:2.94 ± 2.11; Control:2.87 ± 1.69 | NA | 34 (18/16) | 1.0–1.5 | 6 | CTX | 12 | NA/0 | Methylprednisolone 0.5 g iv for first 3ds, 0.8 mg/kg.d p.o. CCB or ACEI/ARB |
Liu et al. 2010 [26] | Nephritic syndrome | MMF:1.09 ± 0.27; Control:1.04 ± 0.29 | MMF:2.6 ± 1.2; Control:2.2 ± 0.72 | NA | 40 (20/20) | 1.5 | 6 | LEF | 6 | NA/0 | Prednisone 0.8 mg/kg.d in both MMF and control; |
Liu et al. 2014 [27] | Proteinuria > 1 g/d; Scr < 3 mg/dl; CrCl > 50/1.73 m2 Grade ≥ III | MMF:1.5 ± 0.4 Control:1.4 ± 0.4 | MMF:2.83 ± 0.65 Control:2.77 ± 0.81 | MMF:141 ± 15.4 Control:134 ± 17.7 | 84 (42/42) | 1.5 g | 18 | CTX | 18 | NA/0 | Prednisone 0.8–1.0 mg/kg.d in both groups; CCB or ACEI/ARB antiplatelet when needed |